Overview SHR-1701 in Patients With Recurrent/Metastatic Scchn Status: Recruiting Trial end date: 2023-01-01 Target enrollment: Participant gender: Summary This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN Phase: Phase 2 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.